TLK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Su-014813 (SCHEMBL902507)	1.00	3/20
Su-014813 (SCHEMBL1249521)	1.00	3/20
Su-014813 (SCHEMBL2334599)	1.00	3/20
Su-014813 (SCHEMBL2334610)	1.00	3/20
Su-014813 (SCHEMBL4500929)	1.00	3/20
Su-014813 (SCHEMBL4500940)	1.00	3/20
Su-014813 (SCHEMBL3367367)	0.93	3/20
Su-014813 (SCHEMBL3367375)	0.93	3/20
SCHEMBL13711974	0.86	3/20
SCHEMBL4492142	0.82	3/20
SCHEMBL4492147	0.82	3/20
SCHEMBL4492152	0.82	3/20
SCHEMBL4503839	0.82	3/20
SCHEMBL13712019	0.82	3/20
SCHEMBL12335939	0.80	3/20
SCHEMBL5830179	0.79	3/20
SCHEMBL5830182	0.79	3/20
SCHEMBL4484145	0.79	3/20
SCHEMBL4484149	0.79	3/20
SCHEMBL4493899	0.79	3/20

Clinical trials — most relevant to TLK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK	PHASE3	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients	PHASE2	RECRUITING
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TLK1 binder may also engage these)

Protein	Name	Similarity
TLK2	Serine/threonine-protein kinase tousled-like 2	1.000	landscape →
Q90ZY6	—	0.999	Q90ZY6 →
O55047	—	0.998	O55047 →
Q8C0V0	—	0.994	Q8C0V0 →
Q1ECX4	—	0.994	Q1ECX4 →
Q08CW1	—	0.992	Q08CW1 →
F1LTE0	—	0.972	F1LTE0 →
Q9ERG2	—	0.971	Q9ERG2 →
Q8BIE6	—	0.971	Q8BIE6 →
Q8WXI2	—	0.971	Q8WXI2 →
Q8BWW9	—	0.971	Q8BWW9 →
Q7YQL6	—	0.971	Q7YQL6 →
PRKD1	Serine/threonine-protein kinase D1	0.971	landscape →
P83094	—	0.971	P83094 →
Q8BJA3	—	0.971	Q8BJA3 →
Q7YQL5	—	0.970	Q7YQL5 →
O60890	—	0.970	O60890 →
Q6NT76	—	0.970	Q6NT76 →
Q8TAV0	—	0.969	Q8TAV0 →
Q9NZI7	—	0.969	Q9NZI7 →
KIF23	Kinesin-like protein KIF23	0.969	landscape →
Q60611	—	0.969	Q60611 →
Q9R1D7	—	0.969	Q9R1D7 →
Q922G2	—	0.969	Q922G2 →
Q58A45	—	0.969	Q58A45 →
Q8K1Y2	—	0.968	Q8K1Y2 →
Q13033	—	0.968	Q13033 →
A1L1C7	—	0.968	A1L1C7 →
Q9P2Q2	—	0.968	Q9P2Q2 →
Q9HCD6	—	0.968	Q9HCD6 →